These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20515697)

  • 21. Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity assay achieves better tumor response.
    Lau GI; Loo WT; Chow LW
    Biomed Pharmacother; 2007 Oct; 61(9):562-5. PubMed ID: 17913448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells.
    Liang CH; Shiu LY; Chang LC; Sheu HM; Kuo KW
    Mol Nutr Food Res; 2007 Aug; 51(8):999-1005. PubMed ID: 17639997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgeons: A Future Role in Clinical Trials?
    Rusch VW
    Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ab initio phenomenological simulation of the growth of large tumor cell populations.
    Chignola R; Del Fabbro A; Pellegrina CD; Milotti E
    Phys Biol; 2007 Jun; 4(2):114-33. PubMed ID: 17664656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
    Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM
    Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S;
    Cancer Lett; 2008 Jun; 264(1):44-53. PubMed ID: 18280644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A model of TLR4 signaling and tolerance using a qualitative, particle-event-based method: introduction of spatially configured stochastic reaction chambers (SCSRC).
    An G
    Math Biosci; 2009 Jan; 217(1):43-52. PubMed ID: 18950646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A four-dimensional simulation model of tumour response to radiotherapy in vivo: parametric validation considering radiosensitivity, genetic profile and fractionation.
    Dionysiou DD; Stamatakos GS; Uzunoglu NK; Nikita KS; Marioli A
    J Theor Biol; 2004 Sep; 230(1):1-20. PubMed ID: 15275995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of tumor spheroids to radiation: modeling and parameter estimation.
    Bertuzzi A; Bruni C; Fasano A; Gandolfi A; Papa F; Sinisgalli C
    Bull Math Biol; 2010 Jul; 72(5):1069-91. PubMed ID: 19915922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doubling back on centromere 17 in early breast cancer.
    Bedard PL; Desmedt C
    Lancet Oncol; 2010 Mar; 11(3):216-7. PubMed ID: 20202603
    [No Abstract]   [Full Text] [Related]  

  • 36. Order-of-magnitude estimates of latency (time to appearance) and refill time of a cancer from a single cancer 'stem' cell compared by an exponential and a logistic equation.
    Anderson KM; Rubenstein M; Guinan P; Patel M
    In Vivo; 2012; 26(2):183-9. PubMed ID: 22351656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico oncology: exploiting clinical studies to clinically adapt and validate multiscale oncosimulators.
    Stamatakos GS; Kolokotroni E; Dionysiou D; Veith C; Kim YJ; Franz A; Marias K; Sabczynski J; Bohle R; Graf N
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():5545-9. PubMed ID: 24110993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
    Barbarossa MV; Kuttler C; Zinsl J
    Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On a mathematical model of tumor growth based on cancer stem cells.
    Tello JI
    Math Biosci Eng; 2013 Feb; 10(1):263-78. PubMed ID: 23311372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.